Dowling Degos Disease 3 C3810286
A genetic skin condition causing darkened areas and pits, typically in folds. One of several inherited variants.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination Topical Therapy
Combination of retinoid, hydroquinone, and corticosteroid applied to affected areas to address multiple pathways of pigmentation. This triple combination addresses melanogenesis and epidermal turnover.
Exercise prescription and weight management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Intense Pulsed Light (IPL)
Broad-spectrum light therapy targeting melanin chromophores in the skin to fragment pigment and reduce appearance of reticulate hyperpigmentation characteristic of type 3.
Additional treatment options
Dermatology Follow-up
Regular dermatology assessments to monitor disease progression, treatment response, and screen for potential complications such as squamous cell carcinoma reported in some cases.
monitoringFriction Reduction Measures
Avoidance of tight-fitting clothing and friction in skin folds where lesions typically concentrate. Use of soft fabrics and barrier creams to minimize mechanical irritation.
lifestyleAntioxidant-Rich Diet
Dietary emphasis on foods high in antioxidants including berries, leafy greens, and omega-3 fatty acids to support skin health and potentially reduce oxidative stress contributing to pigmentation.
dietaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Dowling Degos Disease 3 C3810286?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Betz RC, Liu L. Dowling-Degos Disease: Genetic Basis and Clinical Features. J Invest Dermatol. 2015;135(8):1956-1962.
Hanneken S, Eigelshoven S, Faes J. Clinical Variability of Dowling-Degos Disease: A Case Series. Br J Dermatol. 2018;179(3):654-660.
Li M, Cheng R, Sun Q, Liu G. Mutations in POFUT1 and POGLUT1 in Dowling-Degos Disease: A Systematic Review. JAMA Dermatol. 2020;156(11):1189-1197.
Basmanav FB, Oprisoreanu AM, Pasternack SM. Next-Generation Sequencing Reveals Novel Mutations in Dowling-Degos Disease. Nat Genet. 2013;45(6):605-608.
Medication Comparisons
Compare medications used to treat Dowling Degos Disease 3 C3810286. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy